ArticleScientific reports2026
Associations of the insulinemic potential of diet and lifestyle with metabolic dysfunction-associated steatotic liver disease (MASLD) risk in adults with type 2 diabetes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes mellitus (T2DM), largely due to shared metabolic risk factors such as insulin resistance and obesity. This study aimed to examine the associations between these indices and the likelihood of MASLD in adults with T2DM. In this cross-sectional study, adults with T2DM were recruited. Dietary intake and lifestyle behaviors were assessed using validated questionnaires, and insulinemic indices were calculated accordingly including the empirical dietary index for hyperinsulinemia (EDIH), the empirical dietary index for insulin resistance (EDIR), the empirical lifestyle index for hyperinsulinemia (ELIH), and the empirical lifestyle index for insulin resistance (ELIR). Lifestyle, and metabolic variables, the odds ratio for MASLD in the highest EDIR quartile was 7.81 (p = 0.001), and for ELIH it was 8 (p < 0.001), and it was 3.21 (p = 0.032) for ELIR. No significant associations were observed for EDIH. Dietary and lifestyle patterns with greater insulinemic potential may contribute to MASLD risk in individuals with T2DM. These findings highlight the importance of insulin-modulating dietary strategies in the prevention and management of liver complications in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.